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Abstract The Scottish Structural Proteomics Facility was
funded to develop a laboratory scale approach to high
throughput structure determination. The effort was suc-
cessful in that over 40 structures were determined. These
structures and the methods harnessed to obtain them are
reported here. This report reflects on the value of auto-
mation but also on the continued requirement for a high
degree of scientific and technical expertise. The efficiency
of the process poses challenges to the current paradigm of
structural analysis and publication. In the 5 year period we
published ten peer-reviewed papers reporting structural
data arising from the pipeline. Nevertheless, the number of
structures solved exceeded our ability to analyse and
publish each new finding. By reporting the experimental
details and depositing the structures we hope to maximize
the impact of the project by allowing others to follow up
the relevant biology.
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Introduction
Structural biology is firmly embedded as a crucial tool for
the molecular biologist, whether the interest is academic or
commercial. The genome sequencing revolution of the
1990s transformed the biological landscape and to remain
relevant to the scale of this new information, structural
biology had to accelerate its pace of discovery. The
Scottish Structural Proteomics Facility (SSPF) comprised
of four partner institutions: the Universities of St Andrews,
Dundee, Glasgow and Warwick. The Structural Proteomics
of Rational Targets (SPoRT) laboratory situated at the
University of St Andrews was established with the focus of
developing small scale high throughput structural biology
and to facilitate collaboration with other universities.
Much larger international efforts have focussed on
productivity and throughput as exemplified by the NIH
Protein Structure Initiative in the USA, Protein 3000 in
Japan, Structural Proteomics in Europe (SPINE) [1] and
the international Wellcome Trust Structural Genomics
Consortium (SGC) [2]. Our remit was to generate struc-
tures, publications and to facilitate access for ‘‘non-struc-
tural’’ labs to structural biology. The ‘‘high throughput’’
lab commenced work in 2004 and focussed on develop-
ment of efficient strategies for target selection, cloning,
protein production, crystallization and crystal structure
determination. Due to demands for higher throughput,
automated equipment was employed at several key stages
in the pipeline.
We chose targets against the following criteria: obtain-
ing a structure was likely to be tractable (in essence this
meant expression in Escherichia coli); the protein was
likely to have a novel structure; the structure had the
potential to either underpin antibiotic development or
illuminate some defined aspect of biology or biochemistry.
As we discuss, one of the significant challenges was to
balance choice of ‘‘publishable’’ target work against the
work of running the pipeline and the tractability of target
(including any subsequent biochemical investigation).
Target selection thus differed from many other efforts
which focus on folds predicted to be ‘‘novel’’ (exemplified
by the NIH efforts) or on comprehensive coverage of a
functional class (such as the focus on short chain dehy-
drogenases and kinases of the SGC).
During the build up of the SPoRT pipeline, we operated
structure determination in essentially a traditional manner,
in that projects were processed without automation in a
sequential manner. This was because the funding imposed
a number of output milestones which had to be met, thus
there are ‘‘high throughput’’ structures and ‘‘low through-
put’’ structures. The St Andrews laboratory was funded by
a combination of sources and its staff complement con-
sisted primarily of five post-doctoral research associates
(PDRA) and two technicians. In 4 years, we have cloned
more than 350 genes resulting in the production of 165
proteins from which 42 have yielded crystal structures.
This represents about 25% of purified proteins that made it
to crystal structure. Another measure of efficiency is that in
its lifetime the pipeline delivered over two structures per
PDRA per year. Given that the pipeline only became
operative from the second year, the efficiency metrics by
the end of the project were significantly higher than the
beginning. However, the success of the pipeline outstripped
our ability to analyse and follow up the structures. In this
report, we provide a detailed account of the pipeline, the
experimental structural biology and highlight some of the
issues we faced. This strategy allows others to reproduce
the experiments and to pursue the biological implications
of our work.
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Materials and methods
Bioinformatics analyses for target selection
Proteins were submitted to the pipeline as cohorts of tar-
gets; collection of genes with a common theme or source.
Proteins were then analysed using a standard suite of
analyses: SignalP 3.0 to detect signal peptides which
indicate the protein would otherwise normally be exported
from the cytoplasm [3]; TMHMM2 to detect transmem-
brane regions which may reduce protein solubility [4]; and
RONN and PONDR to analyze the sequence for predicted
disordered regions which are believed to interfere with
crystallization [5, 6]. As a result of these analyses, trun-
cations were made in a few cases where the prediction
suggested significant disorder at the C- or N- termini,
signal peptides or transmembrane regions. BLAST sear-
ches of the PDB were carried out to establish the originality
and potential impact of the structure. Targets were also
analysed using the pI versus GRAVY crystallization pre-
dictor plot as described in [7]. This work was initially
carried out manually or by basic PERL scripts. However, a
core part of the SSPF was to develop improved techniques
for target selection, so in order to streamline and improve
the ease and reliability of target selection we developed an
automated system for carrying out sequence analysis called
TarO [8]. TarO runs a suite of analyses on a target
sequence including orthology detection and returns a
summarised view of the findings as well as an annotated
multiple sequence alignment that assists in the identifica-
tion of domain boundaries and disordered regions. The
system is web-accessible and has been used extensively
within the SSPF as well as by external users world-wide. In
addition to TarO, three techniques for crystallisation pro-
pensity prediction were also developed. The OB-Score [9]
combines hydrophobicity and predicted pI within a statis-
tical framework, the ParCrys algorithm combines more
features of the sequence [10] while XANNpred (manu-
script submitted) is a machine-learning technique that
includes a broad range of properties including predicted
secondary structure. TarO presents results sorted by Par-
Crys and the OB-Score to highlight proteins which may be
more amenable to processing in the SSPF high-throughput
pipeline. While TarO and the crystallisation predictors
were not applied in all structures output by SSPF, they
were input to decision making processes in the later years
of the project.
Genome-wide scale target selection tools
We also developed bioinformatics protocols for large-scale
target selection. A round of target selection was conducted
to select tractable prokaryotic proteins expected to be rel-
evant to human biology. The 657,391 proteins in the CMR
(‘Omniome’) database [11] was the starting point for this
work. The progress of these proteins through the target
selection filters is summarised in Table 1. Proteins pre-
dicted to be amenable to producing diffraction-quality
crystals (OB-Score C 5) were searched against Ensembl
human [12] with PSIBLAST [13], which identified 55,405
matches with expected structural similarity according to
published thresholds [14]. In order to explore novel struc-
ture space, proteins with a match to the PDB [15] were
excluded, leaving 4,461 proteins. Uniprot [16] identifiers
were inferred to provide a mechanism for obtaining pre-
calculated annotations, particularly Pfam [17] and Gene
Ontology (GO) [18] data. Proteins were excluded by the
criteria of one or more predicted TMHMM2 transmem-
brane regions, sequence length outwith 60–600 amino
acids, and more than 20% predicted SEG low-complexity
[19]. A total of 344 Pfam families were inferred for 3,008
proteins that passed the above filters. The total set of
sequences from the 344 Pfam families were searched
against the PDB (BLASTP, 1E-6, 90% identify, 90% query
coverage) to exclude proteins where a homology modelling
template was available. The final filtered set contained
1,329 proteins from 143 Pfam families. These proteins
were then ranked according to OB-Score, and a custom
scoring system ‘SOFA’ (see below).
Table 1 CMR target selection
summary
a Matches defined by Rost
curve [14]
b Uniprot identifiers inferred by
perfect sequence match or
BLASTP (1E-6, 90% query
coverage, 90% identity)
Filter summary No. of proteins post filtering
All CMR proteins 657,391
OB-Score C 5 197,000
PSIBLAST matcha to Ensembl human protein 55,405
No PSIBLAST matcha to PDB 4,461
Assign UniProt IDb 4,306
No TMHMM transmembrane regions & B20% SEG low-complexity,
sequence length 60–600 amino acids
3,508
Infer Pfam family 3,008 (344 families)
No structure in Pfam family 1,329 (143 families)
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A Gene Ontology-based scoring system (Specificity Of
Functional Annotation, ‘SOFA’) was implemented to
estimate the extent of available functional annotation for
candidate targets, because functional annotation is often
important for interpretation of new protein structures. The
GO term with the least number of children was the starting
point for calculating a protein’s SOFA score. From this
term, the ratio of the parent to child terms was calculated;
higher scores indicated more parents and therefore esti-
mated more knowledge was available about the protein’s
function. Where proteins had leaf-node GO term(s) the
SOFA score was always higher than for proteins with no
leaf-node GO term. Also, a greater number of leaf node
terms corresponded to higher scores.
Further large-scale target selection was conducted with
the aim of identifying tractable proteins relevant to
Staphylococcus aureus therapeutics development. A set of
253 identifiers were taken from the literature [20, 21],
indicating genes essential for infectivity in mouse models
and/or essential for viability for growth in rich media.
These were mapped to 1637 S. aureus proteins in CMR,
corresponding to 1 MSSA (MSSA476) and 5 MRSA
(MRSA252, Mu50, COL, MW2, and N315) strains. These
proteins were subject to a series of filters similar to those
described above. The filtering criteria were OB-Score C 3,
\2 TMHMM2 transmembrane regions, B20% SEG low-
complexity, sequence length 60–600 amino acids. PSI-
BLAST matches to PDB and Ensembl human proteins
were excluded according to published thresholds. Matches
to human proteins were excluded because these were
considered to be less attractive therapeutic targets. Pfam
matches were inferred, leaving 51 proteins from 36 Pfam
families and 50 proteins without a Pfam match. SOFA
scoring was applied to these 101 proteins and further
analyses of these proteins including TarO and literature
searching proposed a final set of 20 targets from 11 func-
tional categories. This final set of 20 S. aureus proteins
were submitted to the pipeline for production.
Cloning
With the exception of purified proteins provided by col-
laborators, open reading frames (ORFs) of all targets were
cloned using a modified version of the Gateway cloning
system. Each target was cloned with an N-terminal TEV
protease cleavable Hisx6 tag, with the BP recombination
site relocated out of the cloning sequence. Target genes
were amplified using one common and two gene-specific
primers. The common primer, encoding the attB1 recom-
bination site, RBS, ATG start codon, six histidine residues
and TEV protease site (Fig. 1) was generated by PCR. The
primers used for the above process were 50-GGGGACAA
GTTTGTACAAAAAAGCAGGCTTCGAAGGAGATATAC
ATATG-30 (designated ATTF; attB1 site is in italics) and
50-GCCCTGAAAATACAGGTTTC-30 (designated ATTR)
with template of NdeI/NcoI-DNA fragments released from
pEHISTEV plasmid DNA [22]. PCR products thus gener-
ated were purified by ethanol precipitation and resuspended
to a final concentration of 4 lM. Target genes were
amplified in PCR reactions consisting of 5 ll of each pair
of gene-specific primers (10 lM), 2.5 ll of the common
primers, 5 ll of dNTP mixture (200 lM each), 10 ll of
thermo polymerase buffer (59) containing 2 mM MgSO4
and 4% DMSO, 2 units of Pfu DNA polymerase and 10 ng
of DNA template in a total volume of 50 ll. Two-stage
PCR amplifications were carried out in a 96-well formatted
PCR plate. After denaturing the template at 95C for
5 min, amplifications were carried out at 95C for 1 min,
Tm-5 for 1 min and 72C for 4 min for 5 cycles and then
followed by another 25 cycles using the same procedure
except that an annealing temperature of 62C was
employed instead of Tm-5 to increase the specificity of the
amplification. PCR products were cleaned using the PCR
cleaning kit (Promega) and diluted to a concentration of
50 ng/ll.
BP recombination was carried out as described in the
Gateway cloning instruction manual using pDONR221 as
donor vector. The recombination reaction consisted of
100 ng of attB-PCR products, 100 ng of pDONR221 vec-
tor and 1 ll of BP clonase II enzyme mix in TE buffer to a
total volume of 10 ll. The mixture was incubated at 25C
for 1 h and then further incubated at 37C for 15 min
following the addition of 2 ll proteinase K. E. coli DH5a
chemical competent cells were transformed with 2 ll
reaction mix and the transformed cells were spread onto
L-agar plates containing 50 lg/ml kanamycin. Plasmid
DNA was prepared by picking two colonies and cultivating
in separate 10 ml L-broth media containing 50 lg/ml
kanamycin, prior to insert verification by agarose gel
electrophoresis.
Fig. 1 Bar presentation of primers used for gene amplifications at
SSPF. The 50 end common primer (co) is a double-stranded primer
generated by PCR and used for cloning genes with the N-terminal
TEV protease cleavable 69 His tag. The 50 end custom (gene-
specific) primer (cu) contains overlap sequence of 30 bp with the
common primer and the gene specific sequence of 23 bp. The 30 end
custom (gene-specific) primer (cu) contains the gene-specific
sequence of 23 bp and attB2 recombination site of 30 bp. AttB: BP
recombination sites, RBS: ribosome binding site, ATG: start codon,
69 His: six histidine tag, TEV site: TEV site: sequence coding TEV
protease cleavage site and the spacer. Numbers indicate the length of
the primers (bp)
170 M. Oke et al.
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LR recombination was carried out using pDEST14 as
the destination vector with two verified pDONR221 clones.
The recombination reaction contained 100 ng of entry
clone pDONR221 DNA, 100 ng of pDEST14 vector, 1 ll
of LR clonase II enzyme mix in TE buffer to a total volume
of 10 ll. The reaction mixture was incubated for 1 h at
25C and then incubated at 37C for 15 min after adding
2 ll of proteinase K. A total volume of 2 ll of each BP
reaction was transformed into 50 ll of DH5a chemical
competent cells and selected for ampicillin resistance on an
L-agar plate. Two clones were picked and the plasmid
DNA isolated for each LR reaction. The insertion sequence
of each clone was verified and the prepared DNA was
stored at -80C for expression trials.
Small-scale expression
The E. coli competent cells BL21 (DE3), C43 (DE3), and
BL21 (DE3)-CodonPlus (Strategene) were transformed
with the pDEST14 expression vectors. Small-scale
expression trials were carried out in Lysogeny Broth (LB;
10 g Tryptone, 5 g Yeast Extract, 10 g NaCl), Tryptone
phosphate broth (TPB; 20 g Tryptone, 2 g K2HPO4, 2 g
KH2PO4, 5 g NaCl) and auto-induction media, prepared in-
house using the recipe from [23] or purchased as ‘Magic
Media’ (Invitrogen). For LB and TPB cultures, starter
cultures were prepared by inoculating LB supplemented
with ampicillin (final concentration 100 lg/ml) with
freshly-transformed colonies on LB/ampicillin plates, and
incubating overnight at 37C, 200 rpm. Alternatively, the
transformation mix was used directly as inoculum for
starter cultures. Growth media (5 ml) in 50 ml Falcon
tubes was inoculated with overnight starter culture (1:100
dilution factor) prior to incubation at 37C, 200 rpm. At
mid-log growth phase (OD600 * 0.6–0.8), protein
expression was induced with 0.4 mM IPTG. For LB cul-
tures, incubation continued for a further 3 h at 37C for one
set of cultures, whilst another set was incubated at 25C
overnight. TPB cultures were incubated overnight at 25C
and 15C post-induction. For protein expression in auto-
induction media, freshly transformed colonies were used to
inoculate 3-ml auto-induction media supplemented with
100 lg/ml ampicillin (two colonies per target protein).
Cultures were then incubated at 37C, 300 rpm until cul-
tures turned slightly turbid at which point one set was
further incubated at 37C and the other set at 25C, both for
42 h. Cultures were harvested by centrifugation and pellets
were stored at -20C. Cell lysis was achieved either
chemically using Bugbuster HT solution (Novagen) or
mechanically by sonication. Whole cell lysates were ana-
lysed for target protein expression by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS–PAGE;
[24] using pre-cast gels (Invitrogen). For target protein
localization, cell lysates were spun down and the super-
natant was analysed for His6-tagged soluble protein
expression using the BioSprint 15 workstation according to
manufacturer’s instructions (Qiagen). The resulting eluates
were analysed by SDS-PAGE. Soluble protein expression
was scored on the basis of whether protein bands com-
mensurate with the estimated molecular weight were
identified on SDS-PAGE gels. Band intensities were used
to estimate the amount of soluble protein expressed. For
uniformity, protein expression at\5 mg/l (low expression)
was classified as 1S, 5–10 mg/l (medium expression) as 2S,
and [10 mg/l (high expression) as 3S.
Large-scale expression of target proteins
Protein identities were verified by mass spectrometry prior
to scale-up. Overnight starter cultures were used to inoc-
ulate 1–6 l (depending on expression levels obtained from
small-scale solubility screening experiments) LB, TPB or
auto-induction media supplemented with ampicillin. Opti-
mal growth conditions from small-scale expression trials
were replicated for large scale expression. Prior to har-
vesting (centrifugation at 2,4009g, for 30 min at 4C),
1-ml aliquots were analyzed for protein expression and to
estimate final yields. Cell pellets were stored at -80C
until required for purification.
Where appropriate, selenomethionine-labelled proteins
were produced using the method of [25]. Essentially, freshly
transformed BL21(DE3) or B834(DE3) cells served as
inoculum for starter cultures. After overnight incubation,
starter cultures were pelleted and washed 3 times with
phosphate buffer (1 g NH4Cl, 3 g KH2PO4, 6 g Na2H-
PO4  7H2O/l) prior to inoculation (1:20) of selenomethio-
nine-incorporation media prepared as follows: 100 ml
glucose solution (20% glucose, 0.3% MgSO4, 0.01%
Fe2(SO4)3, 0.01% thiamine) was added to 900 ml phosphate
buffer (same as above). The pH of the media was adjusted to
7.4 prior to addition of ampicillin and 50 mg/l L-(?) Sele-
nomethionine. Cells were cultivated at 37C until OD600 was
between 0.8 and 1.0, at which point IPTG was added to a final
concentration of 0.2 mM. Cultures were incubated at 25C
overnight, harvested and stored as described above.
Preparation of His6-tagged tobacco etch virus (TEV)
protease
The E. coli recombinant strain BL21 (DE3)-RIL/pRK793
harbouring a mutant (S219V) of the catalytic domain of
TEV protease was kindly donated by Partho Ghosh
(Department of Chemistry and Biochemistry, University of
California). This construct expresses as a maltose-binding
protein (MBP) fusion protein that auto-cleaves in vivo,
resulting in the TEV protease catalytic domain with
The Scottish Structural Proteomics Facility 171
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uncleavable N-terminal His6 and C-terminal polyarginine
tags [26]. Following protein expression at 25C, the His6-
TEV protease was purified by nickel-immobilized metal
affinity chromatography (Ni2?-IMAC), followed by
desalting chromatography. Aliquots (5 mg/ml) of TEV
protease were prepared and stored at -80C.
Purification
Cell pellets were resuspended in buffer A (see below for all
buffer constituents) supplemented with Dnase1 (Sigma) and
EDTA-free protease inhibitor cocktail tablets (Roche) prior
to cell lysis on ice using the One Shot cell disruptor (Con-
stant Systems Ltd), continuously cooled with cold tap water.
Cell lysate was clarified by centrifugation at 39,0009g for
1 h at 4C and the supernatant was filtered using a 0.45 lm
filter (Millipore) prior to purification. Fully-automated
purification was carried out on the AKTAxpress chroma-
tography system using pre-packed columns (GE Health-
care). The purification procedure comprised of (1) Ni2?-
immobilized metal affinity chromatography (Ni2?-IMAC)
using buffers B and C for the wash and elution steps
respectively (2) Desalting chromatography (DS) in buffer D
for buffer exchange and removal of imidazole, (3) incuba-
tion with TEV protease for cleavage of the His6 tag, (4)
capture of the His6-tagged TEV protease on a second Ni
2?-
IMAC column and (5) Gel filtration chromatography (GF) in
buffer E to separate out contaminants and aggregates from
the target proteins. A schematic representation of the fully-
automated version is shown in Fig. 2a. To facilitate on-line
off-column cleavage of the His6-tag, a 50-ml superloop
preloaded with His6-TEV protease was incorporated into the
chromatography system. This arrangement facilitated the
direct loading of the DS eluate into the TEV protease-loaded
superloop. For manual purification, the Ni2?-IMAC and
TEV cleavage steps were carried out on the bench, and the
AKTAxpress system was used for DS and GF. All proteins
were purified at room temperature and analysed by SDS-
PAGE. Aliquots of purified proteins were transferred into
thin-walled PCR tubes and flash frozen in liquid nitrogen
prior to storage at -80C.
Buffer A: 20 mM sodium phosphate pH 7.4, 500 mM
NaCl, 10% glycerol, 10–30 mM imidazole
Buffer B: 20 mM sodium phosphate pH 7.4, 500 mM
NaCl, 10% glycerol, 30–50 mM imidazole
Buffer C: 20 mM sodium phosphate pH 7.4, 500 mM
NaCl, 10% glycerol, 300 mM imidazole
Buffer D: 20 mM Tris pH 7.5, 500 mM NaCl, 10%
glycerol
Buffer E: 10 mM Tris pH 7.5, 150 mM or 500 mM
NaCl, 10% glycerol (optional)
Crystallization
The pre-crystallization test (PCT) (Hampton Research) was
used to determine the optimal protein concentration (OPC)
for crystallization trials. All screening experiments were set
up as sitting drops in 96-well crystallization plates at 2 or 3
protein concentrations using either the Cartesian Honeybee
X8 ? 1 in the Hamilton-Rhombix-Thermo integrated crys-
tallization and imager system or an offline Cartesian Hon-
eybee 963. Drop sizes consisting of 0.15 ll protein ?
0.15 ll precipitant (protein concentrations: 19 OPC and 29
OPC) and 0.3 ll protein ? 0.15 ll precipitant (protein
concentration: 19 OPC) were employed. Initially 4 com-
mercial crystallization screens chosen from JCSG?, Clas-
sics, Pegs, pHClear, Anions, Cations (Qiagen) and Wizard I
& II (Emerald Biosystems) were used to screen all proteins.
Eventually, this practice was phased out in favour of 3 sto-
chastic screens [27] prepared in-house alongside the com-
mercial JCSG? screen. All screening experiments were
incubated at 20C and imaged at regular intervals with a
Rhombix-Thermo imager.
The traditional grid screen approach around the initial
hit condition(s) was used primarily for crystal optimization
purposes. If this failed, a stochastic approach to optimiza-
tion was often able to generate suitable single crystals. In
both cases, 24 and 96 well grid/stochastic screens based on
the original mother liquor were designed and built using a
Hamilton Microlab Star and crystallization screens were
then set either as before on one of the robots using nanoliter
volumes or manually using larger ll drop sizes.
Data collection and structure solution
Crystals deemed to be large enough for diffraction
screening were harvested and frozen in liquid nitrogen.
Crystals were characterized in house using a Rigaku
MicromaxTM—007HF Cu anode with VariMax optics
alongside a Rigaku Saturn 944? CCD detector and at
various synchrotron beamlines including BM14, ID14-1,
-2, -4, ID29 and ID 23-1 and -2 at the ESRF and IO2 and
IO3 at the Diamond light source Oxfordshire. HKL2000
[28], MOSFLM [29], SCALA [30] and XDS [31] were all
used at various times to index and scale data. Structures
were phased by whatever method provided the fastest route
to structure and included molecular replacement, sulfur-
single wavelength anomalous diffraction, selenomethio-
nine or heavy atom anomalous diffraction. SHELXC/D/E
[32], SOLVE [33], RESOLVE [34], PHENIX [35] and
CNS [36] and programs implemented under the CCP4
package were used to phase and refine structures [37].
COOT [38] and X-Fit [39] were used for model building.
172 M. Oke et al.
123
CCP4 REFMAC5 [40] was mainly used for refinement,
although some structures were refined with PHENIX. The
quality of all structures was checked with MOLPROBITY
[41] and STAN (http://xray.bmc.uu.se/usf/www.html).
Protein information management system (PIMS)
Given the large volume of data produced by the project and
shared between multiple researchers, a database system
was required to store and process the information. A
companion SPoRT funded project, Protein Information
Management System (PIMS), was initiated at the same
time as the SSPF to provide a laboratory information sys-
tem for the project and other similar projects within the
UK. The PIMS database was used to store and share
experimental results within the project.
Results and discussion
Protein production
All targets have been divided into four groups on the basis
of their origins. (1) Targets from Sulfolobus solfataricus
and Thermoproteus tenax constitute the Archaea group (2)
ORFs from the archaeal Pyrobaculum spherical virus
(PSV) and Sulfolobus islandicus rudivirus (SIRV), along
with ORFs from Mycobacterium and Streptomyces bacte-
riophages were classified as archaeal viruses and bacte-
riophages (3) several pathogenic bacteria make up the
bacterial group; and (4), the eukaryote group consisted of
proteins of human, frog and trypanosome origins. Statistics
for all target groups at various stages of the pipeline are
presented in Table 2. Work was stopped on a few targets
Fig. 2 Protein purification in the SPoRT laboratory. a Schematic representation of the fully automated purification. b Chromatogram of fully
automated purification showing the Ni-NTA, desalting and gel filtration peaks
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for two main reasons: structure of target or ortholog was
determined in our laboratory or elsewhere, or bioinfor-
matics analysis or publications suggested that the targets
were either insoluble or membrane-associated.
The Gateway cloning system was adopted and modified
by the SPoRT laboratory. This cloning strategy is inde-
pendent of restriction enzymes, thus permitting standard-
ized conditions for all of our cloning needs. We found our
modified version to be very efficient for our experiments.
Although PCR reactions using the double-stranded com-
mon and gene-specific primers yielded sufficient PCR
product with our standardized cycles, amplification of GC
rich sequences predictably yielded less PCR product. The
amplified PCR fragments were successfully used for BP
recombination with the protocol described. Transformation
of E. coli cells with 2 ll of the recombination reaction
produced more than 30 colonies on all plates with[99% of
the isolated pDEST14 clones containing the right inserts.
Intermittent sequencing of cloned genes showed that there
was no significant increase in the rate of mutation during
the cloning process. Overall, we found this strategy to be
very robust as over 350 targets were transferred success-
fully to the vector, irrespective of the origin of the gene.
Our expression strategy involved the use of three dif-
ferent variables comprising expression strain, growth
medium and temperature. At the outset of the project, three
E. coli (DE3) expression strains (BL21, C43 and Codon
Plus) were screened for expression. The rationale for
including E. coli BL21(DE3) Codon Plus was to overcome
the anticipated codon bias of archaeal and eukaryotic
genes. However, preliminary results from small scale
expression trials using this strain showed that expression
levels were not improved, and therefore further usage was
discontinued. The C43(DE3) strain is particularly useful
for expression of toxic proteins in E. coli [42, 43]. Initial
expression trials comparing C43(DE3) and BL21(DE3)
cells revealed that the former was particularly beneficial for
expression of the archaeal viral proteins. Overall, 67% of
targets scaled-up were expressed in C43(DE3) and the rest
in BL21(DE3). Growth media employed in our facility
consisted of LB, TPB and auto-induction media. We found
the auto-induction media to be particularly useful for
small-scale expression screening as it facilitated parallel
screening by eliminating the need to measure cell densities
prior to induction. However, since most of the targets were
equally soluble using either TPB or LB, we opted for these
relatively inexpensive and simpler media at the scale-up
stage. Consequently, only 4% of proteins were scaled-up
using auto-induction media, with the rest shared equally
between LB and TPB. Targets scaled-up using auto-
induction media and TPB were those that either expressed
at the 1S level or a minority that did not express at all in LB
media. Overall 72% (190/264) of all expressed targets were
soluble (Table 2), a success rate attributable to the different
expression systems and conditions utilized by the SPoRT
laboratory. Although protein targets of prokaryotic origins
constitute most of the soluble proteins (63%; 120/190), it is
not certain if this is due to the larger number of prokaryotic
targets compared to the others or the use of E. coli for
expression. The majority of soluble targets expressed suf-
ficiently: 27% at the 3S level, 60% at the 2S level, and 13%
at the 1S level. It was tempting to rescue insoluble proteins
using fusion proteins such as MBP and thioredoxin, but we
were not convinced that this would significantly increase
the overall number of soluble targets. Moreover, this would
require more manpower and resources. All soluble proteins
scaled-up successfully, although the volume of media had
to be adjusted depending on the expression level. Typically
2 l of culture was grown for 3S proteins, 4 l for 2S proteins
and 6 l for 1S proteins.
Initially, small-scale cell lysis was carried out using
Bugbuster for convenience. Eventually, this was replaced
by sonication for two main reasons. Firstly, we observed
that higher protein yields of poorly-expressing proteins
were recovered by sonication compared to Bugbuster.
Secondly, we observed that in certain cases, protein yields
were inconsistent between estimated and final yields from
large-scale cultures, presumably due to the detergents in
Bugbuster. Although not convenient for a high-throughput
approach, we adopted sonication in order to eliminate any
ambiguities. A consistent and practical plan was adopted
for the expression process in order to feed the pipeline
Table 2 SPoRT laboratory pipeline scoreboard
Targets Selected Cloned Work stoppeda Expression trials Expressed Soluble Purified Crystals Structure
Bacteria 185 185 32 153 148 120 99 32 22
Archaea 70 70 9 61 60 29 27 11 9
Archaea viruses and
bacteriophages
92 92 18 70 49 32 32 16 9
Eukaryotesb 9 7 – 7 7 9 9 2 2
Total 356 354 59 291 264 190 167 61 42
a Number of targets that were cloned but were not submitted for expression trials
b Two targets were provided as purified proteins by our collaborators
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continuously with proteins for processing. Typically, up to
twenty targets were chosen per week for expression trials.
Concurrently, proteins judged to be soluble from the pre-
vious week and confirmed by mass spectrometry were
prepared in large quantities. The BioSprint 15 workstation,
which can perform 15 nickel pull-down experiments in
about 30 min, expedited sample processing times. Addi-
tionally, the Nanodrop Spectrophotometer was very bene-
ficial as it provided a quick, easy and efficient means for
not only measuring optical densities of cultures, but also
spectra of DNA and proteins. As it was never the case that
all twenty proteins were soluble, up to ten proteins were
scaled up per week and passed on for purification. All
protein expression experiments were routinely carried out
on a weekly basis by one technician, with one PDRA
trouble-shooting problems such as conflicting expression
and mass spectrometry results. Such problems were usually
resolved by repeating the trials and/or gene sequencing.
Affinity tags are ideal for HTP protein purification
because a single chromatography method can be adopted.
The advantages of using the His6-tag are well-documented.
Using either manual or fully-automated purification meth-
ods, we obtained[90% protein purity in sufficient amounts
for about 88% (167/190) of all soluble proteins. A typical
elution profile for proteins purified using the fully-auto-
mated version is shown in Fig. 2b, with clearly identifiable
Ni2?-IMAC, DS and GF peaks. The fully-automated
method, incorporating on-line off-column TEV cleavage,
was made possible by the inclusion of the 50-ml superloop
in-series, as described in Materials and Methods. This
method required no user-intervention once the sample was
applied to the system. Also, the fully-automated method
was less time-consuming, eliminating all manual handling
steps such as sample loading and pooling between each
chromatographic step. TEV cleavage using the fully-auto-
mated method was just as efficient as the manual method.
Up to ten proteins were routinely purified per week by one
technician. However, in several cases, it was difficult to
control the final volume of eluates from all columns lead-
ing up to the GF column, which is limited to a maximum
permissible volume of 5 ml. Elution volumes from chro-
matography steps prior to GF were typically larger than
this volume. The outcome of this was that only 50% of the
purified protein eventually made it to GF. In the latter
stages of the project, after several unsuccessful attempts
were made to rectify the situation, we simply purified all
our targets manually. Consequently, the number of proteins
purified weekly reduced to about six.
Crystallization and crystal structures
All purified protein samples were screened successfully
using the nanolitre-scale Rhombix-Hamilton-Thermo
integrated system. This technology not only reduced
protein production costs (final protein yield was not always
important), but allowed for immediate setting up of crystal
trials soon after purification. As shown in Table 2, 61 of
the 167 purified proteins (37%) formed diffraction-quality
crystals. Despite the nanolitre-scale size of the crystalli-
zation drops, most of the crystals obtained were robust
enough to provide complete datasets suitable for structural
determination. As shown in Table 2, 42 structures have
been solved thus far, representing 25% (42/167) of the
targets that entered crystallization trials. Different phasing
methods were used for structure determination with two-
thirds of the structures using methods other than molecular
replacement (see Table 3). This outcome was anticipated
since most of the SPoRT target sequences did not display
significant homology ([20%) with protein sequences in all
databases at the outset of the project.
Retrospective analysis of target selection
Protein crystallization propensity predictors such as
OB-Score, ParCrys, Xtalpred [44] are widely utilized by
structural genomics groups for target selection. At the
initial stages of this project, some proteins were prioritized
using the pI/GRAVY crystallization predictor, which
groups proteins into clusters A to C, with A being the most
likely to crystallize and C the least likely. Significantly,
proteins in Cluster C are predominantly membrane pro-
teins. Preference was given to proteins that fell into either
cluster A or B. In order to gain further insight into the
efficacy of these predictors, we have carried out a retro-
spective analysis of all structures determined in our labo-
ratory. XtalPred uses a scale of one to five, with one being
the most likely to crystallize and five being the least.
ParCrys predicts sequences to be high-scoring, amenable or
recalcitrant. As shown in Table 3, 44% (18 out of 42) of
the structures would not have been selected if Xtalpred was
used initially to select targets. In the case of ParCrys and
pI/GRAVY, this would have been 34% (14 out of 42) and
39% (16 out of 42) respectively. It is noteworthy to men-
tion here that the pI/GRAVY analysis revealed that the
targets were grouped into either Clusters A or B but never
Cluster C. Consequently, 61% of the targets were exclu-
sively outliers (as denoted in Table 3), and therefore would
not have been selected. Although these results suggest that
the predictors are not perfect, we observe that the ‘un-
crystallizable proteins’ are dominated by the PSV and
SIRV ORFs with sequences unlike any other functionally
characterized protein. Pairwise comparisons reveal that
conflicting outcomes (i.e. one predictor suggests that the
protein is crystallizable whereas another suggests other-
wise) are predicted for 14 proteins by XtalPred versus
ParCrys, 13 proteins by XtalPred versus pI/GRAVY plot
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Table 3 Summary of all SPoRT laboratory crystal structures showing phasing methods, origins and functions of proteins, and retrospective
analysis of all structurally characterized targets using three crystallization predictors
Structures Phasing
method
Origin Function/comments Retrospective analysis of target
selection
PDB code
[reference]
XtalPred ParCrys Cluster
Bacteria
pqsE MR Pseudomonas aeruginosa Quinolone signal response protein 4 High-
scoring
A 2VW8
pqsL Sm P. aeruginosa Probable FAD-dependent
monooxygenase
1 High-
scoring
A 2X3N
PA4511 MR P. aeruginosa Uncharacterized 1 High-
scoring
A 2X5E
PA4631 Lead P. aeruginosa Nucleoside-diphosphate-sugar
epimerase
4 Recalcitrant – 2X4G
PA4715 MR P. aeruginosa Probable aminotransferase 3 Amenable B 2X5D
PA0856 Se-SAD P. aeruginosa Uncharacterized 4 Recalcitrant – 2X3O
FabH MR P. aeruginosa 3-Oxoacyl-[acyl-carrier-protein]
synthase III
2 Recalcitrant A 2X3E
AcsD Se-SAD Pectobacterium chrysanthemi Achromobactin synthetase 4 High-
scoring
A 3FFE [45]
AlcC SIRAS Bordetella bronchiseptica Alcaligin biosynthesis protein C 3 High-
scoring
A 2X0O
DesE Br Streptomyces coelicolor Putative ferric-siderophore receptor
protein
4 High-
scoring
A 2X4L
Fbabb Pt Streptococcus pyogenes Fibronectin binding protein 3 Recalcitrant A 2X5P
MRSA677
(Sar2028)
MR Methicillin-resistant
Staphylococcus aureus
(MRSA)
Asp/Tyr/Phe pyridoxal-50-
phosphate-dependent
aminotransferase
4 High-
scoring
A 2X5F
MRSA681
(Sar2676)
MR MRSA Pantothenate synthetase 1 High-
scoring
A 2X3F
MVAK
(QGJ78)
Sm & Pt MRSA Mevalonate kinase 1 Amenable A 2X7I
SAR0482 Se-SAD MRSA Orn/Lys/Arg decarboxylase family
protein
2 High-
scoring
A 2X3L
SAR1376 Zn MRSA Putative 4-oxalocrotonate
tautomerase
5 Amenable – 2X4K
PPFK
(Q6GIU3)
MR MRSA Putative phosphofructokinase 1 Amenable A 2JG5
TAG
(Q6GG41)
Zn-SAD MRSA DNA-3-methyladenine glycosylase I 1 High-
scoring
A 2JG6
SPT MR Sphingomonas paucimobilis Serine palmitoyl transferase 2 Amenable A 2JG2 [56]
ArdA Pt Transposon Tn916 Antirestriction protein 3 Recalcitrant – 2W82 [57]
ArdB Pt Escherichia coli Antirestriction protein 4 Recalcitrant A 2WJ9
VC1805 MIRAS Vibrio cholerae Hypothetical protein 4 High-
scoring
A 2V1L [58]
Archaea
SSo1986 K and
Pb
S. solfataricus Uncharacterized 1 Amenable – 2X5Q
SSo2273 Fe-SAD S. solfataricus Uncharacterized 3 Amenable – 2X4H
SSo2452 MR S. solfataricus ATPase 4 Amenable – 2W0M [50]
SSo6206 Se-SAD S. solfataricus Uncharacterized 3 Recalcitrant A 2X3D
PCNA MR S. solfataricus DNA processivity factor 3 Amenable A 2IX2 [51]
XPD Se-SAD S. solfataricus DNA repair helicase 3 Amenable – 2VL7 [48]
SSo2462 MR S. solfataricus DNA repair helicase 4 Amenable – 2VA8 [49]
SSo1404 MR S. solfataricus Uncharacterized 3 Amenable – 2IVY
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and 11 proteins by ParCrys versus pI/GRAVY plot. This
discrepancy may be due to different parameters utilized by
the predictors namely; size, homologs in PDB, GRAVY
index and pI. Therefore, it is reasonable to suggest that at
least two predictors should be utilized in order to provide a
wider coverage of crystallization space.
Scientific highlights
Reports describing the crystal structures and biochemical
analyses of 10 SPoRT-generated targets have been pub-
lished in peer-reviewed journals (see Table 3 for refer-
ences). Experimental details of crystal structures yet to be
published are presented in Supplementary information.
Below, we summarize a few examples to highlight the
scientific impact of a few of our accomplishments.
Iron is an essential nutrient and microorganisms syn-
thesize low molecular weight high affinity iron chelators
(siderophores) in order to sequester environmental or host
iron. The synthesis of these compounds is both a potential
antibacterial target and of interest biochemically. We have
reported the crystal structure and biochemical analysis of
AcsD, an enzyme involved in the biosynthesis of
achromobactin from the Gram negative plant pathogen
Pectobacterium chrysanthemi [45] and the structure of
AlcC, a new member of the superfamily, will be reported in
due course. Other antimicrobial targets included those
selected from Pseudomonas aeruginosa, an opportunistic
antibiotic-resistant human pathogen. The Pseudomonas
quinolone signal (PQS) is implicated in both pathogenesis
and formation of biofilms and was of particular interest. In
total eight P. aeruginosa structures have been determined.
Methicillin-resistant Staphylococcus aureus (MRSA) is the
cause of considerable concern in hospitals. We employed
comparative two-dimensional gel analysis and mass spec-
trometry [46, 47] to identify proteins that were either
upregulated or downregulated in MRSA compared to
methicillin-sensitive S. aureus (MSSA), and therefore con-
sidered to be essential with potentially novel folds. Seven
structures have been determined from this target.
Archaeal proteins are frequently used as tools to
understand equivalent proteins in eukaryotes, most partic-
ularly those involved in DNA replication and repair. Of the
61 archaeal targets selected, 60 expressed, about half were
soluble and nine structures were determined. These inclu-
ded crystal structures of two helicases implicated in DNA
Table 3 continued
Structures Phasing
method
Origin Function/comments Retrospective analysis of target
selection
PDB code
[reference]
XtalPred ParCrys Cluster
Ard1 S. solfataricus N-terminal acetylase 3 Recalcitrant – 2X7B
Archaea viruses and bacteriophages
SIRV-ORF114
(CAG38848)
MR Sulfolobus islandicus
rudivirus (SIRV)
Uncharacterized 2 High-
scoring
A 2X4I
SIRV-ORF131
(CAG38830)
Se-SAD SIRV Uncharacterized 4 Recalcitrant – Sm-2X5G;
Dm-2X5H
SIRV-ORF55
(CAG38821)
Zn-SAD SIRV Uncharacterized 5 Recalcitrant – 2X48
SIRV-ORF119
(CAG38829)
Se-SAD SIRV Uncharacterized 5 Recalcitrant – 2X3G
PSV-ORF131 S-SAD Pyrobaculum spherical virus
(PSV)
Uncharacterized 4 Recalcitrant – 2X5C
PSV-ORF137 Se-SAD PSV Uncharacterized 3 Recalcitrant – 2X4J
PSV-ORF165a Se-SAD PSV Uncharacterized 4 Recalcitrant – 2VXZ
PSV-ORF239 Sulphur-
SAD
PSV Uncharacterized 5 High-
scoring
A 2X3M
PSV-ORF126 Zn-SAD PSV Uncharacterized 3 Recalcitrant B 2X5R
Eukaryotes
Ranasmurfin Zn-SAD Polypedates leucomystax Uncharacterized 4 Amenable A 2VH3 [54]
Cathepsin-L
mutant
MR Human Silica polymerization 3 Amenable A 2VHS [59]
The PDB code for each structure is indicated
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repair: XPD from S. tokodaii [48] and hel308 from S.
solfataricus [49], a RadA paralog [50] and a heterotrimeric
PCNA sliding clamp [51].
Sulfolobus islandicus rudivirus (SIRV) and Pyrobacu-
lum spherical virus (PSV) are dsDNA viruses that infect
archaea and their proteins show little or no detectable
homology to any proteins of known function [52, 53]. We
reasoned that structural data from these viruses could help
elucidate viral protein function and improve our under-
standing of viral evolution. The virus genomes (48 ORFs
from SIRV and 45 ORFs from PSV) were of a suitable size
for us to attempt complete coverage. We were able to
determine eight structures having cloned and attempted to
express all genes.
Biological research is of course very broad but we were
able to contribute to a number of local projects by pro-
viding structural data. The most striking was a novel pro-
tein harvested from the foam nests of Polypedates
leucomystax, a tropical frog species from Malaysia. The
crystal structure of the protein, named ranasmurfin,
revealed intra- and inter-molecular cross-links featuring the
lysine-tyrosine quinone (LTQ) co-factor. At 1.16 A˚ reso-
lution, the amino acid sequence was identified directly
from the electron density map and verified by mass spec-
trometry to be a novel protein [54].
Conclusions
It is clear from many studies that structure determination
can be largely automated and the efficiency greatly
improved. What is more, our effort demonstrates that this
can be carried out on a relatively small scale and be
focused to deliver results to the scientific community. The
ability to run such a pipeline appears to be a skill in itself.
Our own efficiency improved year on year as new working
practices and approaches developed with experience.
Despite this success, we have not been able to reach the
point of guaranteeing a structure for every target nor in
being able a priori to identify which targets will give
structures. Target selection is improving and new tools are
emerging that should continue to drive up the target to
structure ratio (reviewed in [55]), although this is not the
same as a structure for every biological target. A small
group can gain efficiency by being able to adjust and alter
procedures. For example, we found the use of heavy atoms
a very efficient first attempt to solve structures rather than
always proceeding to selenomethionine.
Our experience is that a structural biology laboratory
within a collaborative centre, bringing the techniques of
modern structural biology to bear on novel problems, has
some advantages. The pipeline has the capacity to move
very quickly to respond to a scientific need. Personnel who
run the pipeline improved in efficiency over the time of the
project. In a collaboration, the expertise of those carrying
out the structural biology can be leveraged in the analysis
of the structure, design and interpretation of subsequent
experiments.
Efficiency and automation require significant intellec-
tual resources. We observe that in this lies an issue for the
future. Even in our relatively small scale effort, we were
unable to match the productivity of the pipeline at gener-
ating structures with publication. Only in cases where
targets were carefully chosen in advance or the structure
was immediately scientifically significant, were we able to
follow this more traditional path to publications. With
collaborations, we were able to perform significant bio-
chemical analysis for some proteins. However, as we
report, many structures have been determined with very
limited or no analysis. By fully reporting the experimental
detail and depositing the data, we aim to prompt others to
perform this analysis.
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